|
EQS-Ad-hoc: Alzchem Group AG / Key word(s): Change in Forecast Alzchem Group AG is significantly raising its earnings forecast for the fiscal year 2023 despite a slightly lower sales expectation. Group EBITDA is expected to grow to approximately EUR 80 million (original forecast: up to EUR 70 million). Group sales are expected to be at or slightly below the previous year’s level of EUR 542.2 million; this is slightly below the most recent forecast. The higher earnings forecast is based primarily on the very positive development of the high-margin specialty chemicals business. Particularly noteworthy in this respect are the products from the Human Nutrition (Creapure®) and Animal Nutrition (Creamino®) businesses, as well as the guanidine salts (nitroguanidine). The forecasts for fiscal year 2023 made in the consolidated financial statements as of 31 December 2022 and last specified in July 2023 are therefore adjusted overall as follows:
End of Inside Information
18-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||||||||||||||
| Language: | English |
| Company: | Alzchem Group AG |
| Dr.-Albert-Frank-Str. 32 | |
| 83308 Trostberg | |
| Germany | |
| Phone: | +498621862888 |
| Fax: | +49862186502888 |
| E-mail: | ir@alzchem.com |
| Internet: | www.alzchem.com |
| ISIN: | DE000A2YNT30 |
| WKN: | A2YNT3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart |
| EQS News ID: | 1752073 |
| End of Announcement | EQS News Service |
|
|
1752073 18-Oct-2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
